Groupama Asset Management Trims Stake in Vertex Pharmaceuticals

Institutional investor reduces holdings in biotech firm by 29.2% in Q3

Mar. 19, 2026 at 9:38am

Got story updates? Submit your updates here. ›

Groupama Asset Management, an institutional investor, has reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 29.2% in the third quarter, according to a recent SEC filing. The firm now owns 43,381 shares of the pharmaceutical company's stock, down from 61,297 shares previously.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. Changes in institutional ownership can provide insights into investor sentiment around a company's prospects and performance.

The details

According to the SEC filing, Groupama Asset Management sold 17,916 shares of Vertex Pharmaceuticals in the third quarter. The firm's holdings in Vertex are now valued at $16,990,000, down from $24,000,000 previously. Vertex Pharmaceuticals' stock price has fluctuated between $362.50 and $515.67 over the past 52 weeks.

  • Groupama Asset Management reduced its Vertex Pharmaceuticals stake in the 3rd quarter of 2025.

The players

Groupama Asset Management

An institutional investor that has reduced its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Groupama Asset Management's Vertex Pharmaceuticals holdings suggests a shift in investor sentiment around the biotech firm, though the reasons behind the sale are not entirely clear. Vertex remains a leader in its field, but changes in institutional ownership can provide valuable insights into the company's performance and outlook.